First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study.

ABSTRACT:

Background

For several years, the AXL tyrosine kinase receptor, a member of the Tyro3-Axl-Mer (TAM) family, has been considered a new strategic target in oncology. AXL overexpression is common in solid tumors and is associated with poor prognosis. In this context, the detection of a subset of circulating tumor cells (CTCs) that express AXL (AXL⁺ CTCs) could be clinically relevant.

Methods

Immunostaining was performed to assess AXL expression in human breast cancer cell lines. The optimal conditions were established using flow cytometry. Spiking experiments were carried out to optimize the parameters of the CellSearch^® system detection test. CTC enumeration and AXL expression were evaluated in patients with metastatic breast cancer (mBC) before treatment

SUBMITTER: Bardol T 

PROVIDER: S-EPMC10807582 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature